Thyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Gastroenterology and Hepatology"
DOI: 10.1111/jgh.16874
Abstract: Resmetirom, the first FDAâapproved drug for nonalcoholic steatohepatitis (NASH) with fibrosis in obese patients, when combined with lifestyle modifications, improves NASH resolution and reduces fibrosis by at least one stage. Low thyroid hormone (T3) levels… read more here.
Keywords: thyromimetics masld; novel molecules; masld unveiling; unveiling novel ... See more keywords